drugset / Trial / NCT01730014

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

NCT01730014

Phase 1 Completed 70 enrolled Novo Nordisk A/S
RandomizedSingle-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneous NNC0148-0000-0287 (insulin 287) in healthy subjects and in subjects with type 1 diabetes

Timeline

Start
2012-10
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0148-0000-0287 Unknown Subcutaneous
Subject insulin glargine Protein / enzyme biologic Subcutaneous